Cedelizumab

Drug Profile

Cedelizumab

Alternative Names: Monoclonal antibody OKT-4; OKT-4 antibody; OKT-4A; Orthoclone OKT4; Orthoclone OKT4A; RWJ 49004

Latest Information Update: 08 Aug 2002

Price : $50

At a glance

  • Originator Ortho-McNeil
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 30 Jun 1997 A study has been added added to the pharmacokinetics, adverse events and Transplant Rejection therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top